MAPK1 and melanoma: An earlier study revealed that constitutive activation of B-RAFV600E mutant activates the MEK/ERK pathway and enhances melanoma cell proliferation whereas inhibition of the B-RAFV600E mutant by vemurafenib decreases melanoma cell proliferation58.